For decades, oncologists have wrestled with a difficult paradox in treating colon cancer: a promising anti-inflammatory drug seemed to work for some patients but not for others, leaving doctors without a clear path forward until a re-examination of old evidence revealed a hidden clue in the
Today we are joined by Ivan Kairatov, a biopharma expert with deep insights into the intersection of technology and medical innovation. For decades, the goal of HIV treatment has been management—using antiretroviral therapy to suppress the virus to undetectable levels. A true cure has remained
Beyond the primary battle against tumors, many cancer patients face a debilitating secondary war against cachexia, a profound wasting syndrome that silently erodes the body and spirit. This severe metabolic condition, marked by unintentional weight loss and muscle deterioration, significantly
In the high-stakes world of biopharmaceutical development, the line between a groundbreaking success and a costly failure is often defined by the unforgiving logic of statistical significance, a reality Nektar Therapeutics recently confronted with its autoimmune drug, rezpegaldesleukin. The company
The intricate dance of cellular machinery required to produce life-saving biologic therapies has long been dictated by a rhythm of chance, but a new era of genomic precision is fundamentally changing the tempo of drug development. For decades, the biopharmaceutical industry has grappled with a
The landscape of cancer immunotherapy was shaken as Arcus Biosciences announced the termination of a pivotal Phase 3 trial for its TIGIT-targeting drug, domvanalimab. The decision, prompted by a finding of "futility," delivers a significant setback to its partner Gilead Sciences and casts further
